Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and ...
SAN DIEGO--(BUSINESS WIRE)--$ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA ...
Credit: Shutterstock / Mr. Kosal California vaccine company Arcturus Therapeutics has announced the launch of a Phase I trial of ARCT-2304, a self-amplifying mRNA (sa-mRNA) vaccine candidate designed ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback